US FDA committee advises against approval of pembolizumab for the neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer

According to the article, the most recent interim analysis of the KEYNOTE-522 had not met the pre-specified threshold for statistical significance and remained immature, with only 53% of targeted event-free survival events and 32% overall survival events having occurred.

Source:

Biospace Inc.